Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs.

Srinivasan A, Gold B.

Future Med Chem. 2012 Jun;4(9):1093-111. doi: 10.4155/fmc.12.58. Review.

2.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Zhu Y, Hu J, Hu Y, Liu W.

Cancer Treat Rev. 2009 Nov;35(7):590-6. doi: 10.1016/j.ctrv.2009.06.005. Epub 2009 Jul 26. Review.

PMID:
19635647
3.
4.

Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.

Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y, Kerbel RS.

Mol Cancer Ther. 2005 Oct;4(10):1484-94.

5.

Insights into oxazaphosphorine resistance and possible approaches to its circumvention.

Zhang J, Tian Q, Chan SY, Duan W, Zhou S.

Drug Resist Updat. 2005 Oct;8(5):271-97. Epub 2005 Sep 9. Review.

PMID:
16154799
6.

The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.

Chen CC, Taniguchi T, D'Andrea A.

J Mol Med (Berl). 2007 May;85(5):497-509. Epub 2007 Jan 13.

PMID:
17221219
7.

Role of mismatch repair and MGMT in response to anticancer therapies.

Casorelli I, Russo MT, Bignami M.

Anticancer Agents Med Chem. 2008 May;8(4):368-80. Review.

PMID:
18473722
8.

DNA repair in resistance to alkylating anticancer drugs.

Kaina B, Christmann M.

Int J Clin Pharmacol Ther. 2002 Aug;40(8):354-67. Review.

PMID:
12467304
10.

Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.

Jiang G, Li LT, Xin Y, Zhang L, Liu YQ, Zheng JN.

Curr Med Chem. 2012;19(23):3886-92. Review.

PMID:
22788764
11.

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

Verbeek B, Southgate TD, Gilham DE, Margison GP.

Br Med Bull. 2008;85:17-33. doi: 10.1093/bmb/ldm036. Epub 2008 Feb 1. Review.

PMID:
18245773
13.

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.

Colella G, Marchini S, D'Incalci M, Brown R, Broggini M.

Br J Cancer. 1999 May;80(3-4):338-43.

14.

Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.

Cai S, Xu Y, Cooper RJ, Ferkowicz MJ, Hartwell JR, Pollok KE, Kelley MR.

Cancer Res. 2005 Apr 15;65(8):3319-27.

15.

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC.

Anticancer Drugs. 2002 Jun;13(5):511-9.

PMID:
12045463
16.

Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents.

Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamali MA.

Mutat Res. 1995 Nov;337(3):179-89.

PMID:
7491121
17.

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Davidson D, Amrein L, Panasci L, Aloyz R.

Front Pharmacol. 2013 Jan 31;4:5. doi: 10.3389/fphar.2013.00005. eCollection 2013.

19.

Emerging cancer therapeutic opportunities target DNA-repair systems.

Ding J, Miao ZH, Meng LH, Geng MY.

Trends Pharmacol Sci. 2006 Jun;27(6):338-44. Epub 2006 May 11. Review.

PMID:
16697054
20.

Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

Jones RB.

Cancer Treat Res. 2002;112:305-22. Review. No abstract available.

PMID:
12481722
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk